WO2008146691A1 - 肝炎の予防又は治療のための医薬組成物 - Google Patents

肝炎の予防又は治療のための医薬組成物 Download PDF

Info

Publication number
WO2008146691A1
WO2008146691A1 PCT/JP2008/059414 JP2008059414W WO2008146691A1 WO 2008146691 A1 WO2008146691 A1 WO 2008146691A1 JP 2008059414 W JP2008059414 W JP 2008059414W WO 2008146691 A1 WO2008146691 A1 WO 2008146691A1
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
prevention
treatment
pharmaceutical composition
alkyl group
Prior art date
Application number
PCT/JP2008/059414
Other languages
English (en)
French (fr)
Inventor
Takaichi Shimozato
Takashi Kagari
Hiromi Doi
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Priority to JP2009516274A priority Critical patent/JPWO2008146691A1/ja
Priority to EP08764487A priority patent/EP2149549A4/en
Publication of WO2008146691A1 publication Critical patent/WO2008146691A1/ja
Priority to US12/624,214 priority patent/US20100081702A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrrole Compounds (AREA)

Abstract

本発明は、肝炎の予防又は治療のための医薬組成物を提供する。 一般式（Ｉ） 【化１】   （式中、 Ｒ１は、Ｃ１－Ｃ４アルキル基を示し、 Ｒ２及びＲ３は、同一又は異なって、水素原子、Ｃ１－Ｃ４アルキル基又はＣ１－Ｃ４アルコキシ基を示し、 Ｘは、硫黄原子又はメチル基が置換した窒素原子を示し、 ｎは、３又は４の整数を示す。） を有する化合物又はその薬理上許容される塩を有効成分として含有する肝炎の予防又は治療のための医薬組成物。
PCT/JP2008/059414 2007-05-25 2008-05-22 肝炎の予防又は治療のための医薬組成物 WO2008146691A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2009516274A JPWO2008146691A1 (ja) 2007-05-25 2008-05-22 肝炎の予防又は治療のための医薬組成物
EP08764487A EP2149549A4 (en) 2007-05-25 2008-05-22 PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEPATITIS
US12/624,214 US20100081702A1 (en) 2007-05-25 2009-11-23 Pharmaceutical composition for prophylaxis or treatment of hepatitis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-138771 2007-05-25
JP2007138771 2007-05-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/624,214 Continuation US20100081702A1 (en) 2007-05-25 2009-11-23 Pharmaceutical composition for prophylaxis or treatment of hepatitis

Publications (1)

Publication Number Publication Date
WO2008146691A1 true WO2008146691A1 (ja) 2008-12-04

Family

ID=40316830

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/059414 WO2008146691A1 (ja) 2007-05-25 2008-05-22 肝炎の予防又は治療のための医薬組成物

Country Status (5)

Country Link
US (1) US20100081702A1 (ja)
EP (1) EP2149549A4 (ja)
JP (1) JPWO2008146691A1 (ja)
TW (1) TW200906389A (ja)
WO (1) WO2008146691A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015505536A (ja) * 2012-01-20 2015-02-23 アクセラ インク． 疾患の処置のための置換された複素環化合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006228A1 (fr) 2000-07-19 2002-01-24 Ube Industries, Ltd. Procede de production de 5-fluorooxyindole et procede de production d'un produit intermediaire de celui-ci
WO2003059880A1 (fr) 2002-01-11 2003-07-24 Sankyo Company, Limited Derive d'amino-alcool ou derive d'acide phosphonique et composition medicamenteuse les contenant
JP2003267974A (ja) * 2002-01-11 2003-09-25 Sankyo Co Ltd アミノアルコ−ル誘導体を含有する医薬組成物
WO2005079788A1 (ja) 2004-02-24 2005-09-01 Sankyo Company, Limited アミノアルコール化合物
WO2006137509A1 (ja) * 2005-06-24 2006-12-28 Daiichi Sankyo Company, Limited Ｐｐａｒ調節剤を含有する医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL359411A1 (en) * 2000-07-13 2004-08-23 Sankyo Company, Limited Amino alcohol derivatives
TW200510300A (en) * 2003-07-11 2005-03-16 Sankyo Co Amino alcohol compounds
JP2006188452A (ja) * 2005-01-06 2006-07-20 Sankyo Co Ltd アミノアルコール化合物を含有する医薬組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006228A1 (fr) 2000-07-19 2002-01-24 Ube Industries, Ltd. Procede de production de 5-fluorooxyindole et procede de production d'un produit intermediaire de celui-ci
WO2003059880A1 (fr) 2002-01-11 2003-07-24 Sankyo Company, Limited Derive d'amino-alcool ou derive d'acide phosphonique et composition medicamenteuse les contenant
JP2003267974A (ja) * 2002-01-11 2003-09-25 Sankyo Co Ltd アミノアルコ−ル誘導体を含有する医薬組成物
WO2005079788A1 (ja) 2004-02-24 2005-09-01 Sankyo Company, Limited アミノアルコール化合物
WO2006137509A1 (ja) * 2005-06-24 2006-12-28 Daiichi Sankyo Company, Limited Ｐｐａｒ調節剤を含有する医薬組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
INOUE K.: "C-gata Kan'en Virus to Cyclosporin A", IGAKU NO AYUMI, vol. 193, no. 12, 2000, pages 951 - 954, XP003004368 *
See also references of EP2149549A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015505536A (ja) * 2012-01-20 2015-02-23 アクセラ インク． 疾患の処置のための置換された複素環化合物

Also Published As

Publication number Publication date
US20100081702A1 (en) 2010-04-01
JPWO2008146691A1 (ja) 2010-08-19
EP2149549A4 (en) 2012-01-04
EP2149549A1 (en) 2010-02-03
TW200906389A (en) 2009-02-16

Similar Documents

Publication Publication Date Title
WO2008108386A1 (ja) 医薬組成物
WO2008021928A3 (en) Hepatitis c virus inhibitors
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
WO2008111441A1 (ja) 医薬組成物
MX2011012628A (es) Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
MY144588A (en) Novel coumarin derivative having antitumor activity
WO2008114817A1 (ja) 新規なアデニン化合物
WO2008114819A1 (ja) 新規アデニン化合物
WO2007138472A3 (en) Triazolopyridazine derivatives
EP1798226A4 (en) TRAIZOL DERIVATIVE
TW200612958A (en) Substituted imidazole derivatives
WO2008114812A1 (ja) Jak阻害剤
WO2008126901A1 (ja) 含窒素複素環化合物およびそれを含有する医薬組成物
MX2010001566A (es) Derivado de aminopirazolamida.
WO2008003854A3 (fr) Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
TW200745104A (en) Multikinase inhibitor
TW200612920A (en) Novel imidazolidine derivatives
WO2008149834A1 (ja) ピリミドジアゼピノン誘導体
WO2008153042A1 (ja) 抗腫瘍剤
WO2009051223A1 (ja) 白内障処置のための医薬組成物
WO2009063990A1 (ja) ベンズアゼピノン化合物
EP1671957A4 (en) THIADIAZOLINDERIVATE
WO2009063897A1 (ja) 皮膚の乾癬予防または改善剤
EP1813270A4 (en) PROTEIN INHIBITORS OF THE HSP90 FAMILY

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08764487

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009516274

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008764487

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE